Pancreatic Cancer Research

ResearcherUniversity of California, San FranciscoActive in the last 2 years

Guido von Figura

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 6 November 2026

Matched on OpenAlex author ID A5085713577. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 2 papers · 2015: 2 papers · 2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 10

  1. Comparison of endoscopic ultrasound-guided fine-needle aspiration and fine-needle biopsy to generate pancreatic cancer organoids: Randomized trial. Co-author DOI 10.1055/a-2257-3171↗
  2. Loss of Wasl improves pancreatic cancer outcome. Co-author DOI 10.1172/jci.insight.127275↗
  3. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. Co-author DOI 10.1172/jci.insight.137809↗
  4. Hes1 Controls Exocrine Cell Plasticity and Restricts Development of Pancreatic Ductal Adenocarcinoma in a Mouse Model. Co-author DOI 10.1016/j.ajpath.2016.07.025↗
  5. Developmental Pathways Direct Pancreatic Cancer Initiation from Its Cellular Origin. Last author DOI 10.1155/2016/9298535↗
  6. Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition. Co-author DOI 10.1038/ncomms8677↗
  7. Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation. Co-author DOI 10.1101/gad.256628.114↗
  8. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ncb2916↗
  9. Dicer regulates differentiation and viability during mouse pancreatic cancer initiation. Co-author DOI 10.1371/journal.pone.0095486↗
  10. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.ccr.2012.10.025↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Maximilian Reichert · 4 shared papers, 2016–2024 · strength 0.41
  2. Roland Michael Schmid · 4 shared papers, 2016–2024 · strength 0.39
  3. Felix Orben · 2 shared papers, 2020–2024 · strength 0.25
  4. Christoph Schlag · 2 shared papers, 2020–2024 · strength 0.25
  5. Alexander Herner · 2 shared papers, 2020–2024 · strength 0.25
  6. Günter Schneider · 2 shared papers, 2020–2024 · strength 0.25
  7. Jens Thomas Siveke · 3 shared papers, 2016–2020 · strength 0.21
  8. Clara Lubeseder–Martellato · 3 shared papers, 2016–2020 · strength 0.21
  9. Johannes Roman Wiessner · 1 shared paper, 2024 · strength 0.18
  10. Zahra Dantes · 2 shared papers, 2020 · strength 0.15
  11. Roland Rad · 2 shared papers, 2020 · strength 0.15
  12. Matthias Hebrok · 4 shared papers, 2012–2015 · strength 0.15
  13. Ana Hidalgo‐Sastre · 2 shared papers, 2016–2020 · strength 0.14
  14. Alexander Kleger · 2 shared papers, 2015–2016 · strength 0.11
  15. John P. Morris · 3 shared papers, 2012–2014 · strength 0.10
  16. Marina Lesina · 1 shared paper, 2020 · strength 0.09
  17. Henrik Einwächter · 1 shared paper, 2020 · strength 0.09
  18. Nilotpal Roy · 2 shared papers, 2014–2015 · strength 0.08
  19. David W. Dawson · 2 shared papers, 2014–2015 · strength 0.08
  20. Grace Kim · 2 shared papers, 2014 · strength 0.08
  21. Lucia Liotta · 1 shared paper, 2020 · strength 0.07
  22. Katja Peschke · 1 shared paper, 2020 · strength 0.07
  23. Marc Eric Martignoni · 1 shared paper, 2020 · strength 0.07
  24. Karin Feldmann · 1 shared paper, 2020 · strength 0.07
  25. Helmut Frieß · 1 shared paper, 2020 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.